Peptide and compounding law · Updated
Compounded tirzepatide and semaglutide: what is legal now
Compounded tirzepatide and semaglutide are not banned outright, but the broad compounding of 2022 to 2024 is over. The FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage on February 21, 2025; its grace periods ended in 2025, and in August 2026 the Fifth Circuit upheld both decisions. Today a 503A pharmacy may compound either drug only for an identified patient, and not as a copy of Ozempic, Wegovy, Mounjaro or Zepbound unless the prescriber documents a significant difference for that patient. A 503B outsourcing facility has no route: neither drug is on the 503B bulks list or the shortage list, and on May 1, 2026 the FDA proposed keeping them off. Telehealth sellers that call a compounded product "generic" or "the same as" the brand have drawn FDA warning letters.
| Date | What happened | Source |
|---|---|---|
| December 19, 2024 | The FDA re-decides the tirzepatide shortage after litigation: resolved | FDA GLP-1 page |
| February 21, 2025 | The FDA declares the semaglutide injection shortage resolved | FDA GLP-1 page |
| March 5 and March 19, 2025 | Tirzepatide: a federal court denies a preliminary injunction (March 5), which ends the FDA's 503A grace period; the 503B grace period ends March 19 | FDA GLP-1 page (March 10, 2025 entry) |
| April 24 and May 22, 2025 | Semaglutide: injunction denied (April 24), ending the 503A grace period; the 503B grace period ends May 22 | FDA GLP-1 page (April 28, 2025 entry) |
| September 9, 2025 | FDA warning letter to a national telehealth company over compounded semaglutide claims | FDA warning letter |
| March 3, 2026 | The FDA announces warning letters to 30 telehealth companies over compounded GLP-1 marketing | FDA press release |
| April 1, 2026 | The FDA explains when a compounded GLP-1 is "essentially a copy", including semaglutide with vitamin B12 | FDA GLP-1 page |
| May 1, 2026 | The FDA proposes not to put semaglutide, tirzepatide or liraglutide on the 503B bulks list; comments closed July 30, 2026; not final as of November 3, 2026 | 91 FR 23431; 91 FR 38719 |
| August 27, 2026 | The Fifth Circuit affirms the FDA in both shortage cases (Nos. 25-10600 and 25-10758, unpublished) | Tirzepatide opinion; semaglutide opinion |
| Supplier | Status | Rule |
|---|---|---|
| 503A pharmacy, prescription for an identified patient, prescriber documents a significant difference (for example a different strength or an excluded ingredient the patient needs) | Lawful if every 503A condition is met | 21 U.S.C. 353a(b)(1)(D); FDA copies guidance |
| 503A pharmacy filling copies without that documentation | Limited: copies may not be compounded "regularly or in inordinate amounts". The FDA does not intend to act at four or fewer prescriptions of a copy a month | 21 U.S.C. 353a(b)(1)(D); FDA copies guidance |
| 503B outsourcing facility, from bulk API | No route: not on the 503B bulks list or the shortage list | 21 U.S.C. 353b(a)(2); FDA GLP-1 page |
| Any compounder using semaglutide sodium or semaglutide acetate | The FDA treats these salts as "different active ingredients" from the approved drugs | FDA, October 1, 2026 |
| Seller of "research use only" semaglutide or tirzepatide to consumers | Unapproved new drugs; a seller was sentenced to 21 months in July 2026 | DOJ, W.D. Mich., July 23, 2026 |
| Retatrutide or cagrilintide | "Cannot be used in compounding under federal law" (FDA) | FDA, October 1, 2026 |
Why the shortage mattered
Compounding is an exception to the rule that a drug needs FDA approval. Two limits in it made the GLP-1 boom possible and then ended it. A 503A pharmacy may not compound "regularly or in inordinate amounts" drugs that are "essentially copies of a commercially available drug product" (21 U.S.C. 353a(b)(1)(D)), and a drug on the FDA's shortage list is not treated as commercially available. A 503B outsourcing facility may compound from a bulk ingredient only if it is on the 503B bulks list or the drug is on the shortage list (21 U.S.C. 353b(a)(2)).
Tirzepatide and semaglutide injections were in shortage from 2022. Once the FDA declared each shortage over, both exceptions closed, subject to the grace periods in the timeline above. The FDA's April 1, 2026 update says it plainly: "Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA's drug shortage list" (FDA GLP-1 page). On November 3, 2026 FDA's shortage database still listed neither drug; liraglutide injection was listed as in shortage.
The courts
The Outsourcing Facilities Association sued over both decisions in the Northern District of Texas. The court denied preliminary injunctions on March 5, 2025 (tirzepatide) and April 24, 2025 (semaglutide), and later granted judgment to the FDA. On August 27, 2026 the Fifth Circuit affirmed both. In the tirzepatide case it held that the compounders had not shown prejudice from any notice-and-comment error and that "the FDA's shortage determination was not arbitrary or capricious" (No. 25-10600); in the semaglutide case, that any such error "was harmless, and the FDA's ultimate action was not arbitrary or capricious" (No. 25-10758). Both opinions are unpublished.
What a 503A pharmacy may still do
A state-licensed pharmacy may compound tirzepatide or semaglutide for an identified patient on a valid prescription, from an ingredient that qualifies (both are components of approved drugs) and under every other 503A condition. The live question is the copy rule. The FDA treats a compounded product as "essentially a copy" when it has the same active ingredient as the approved drug "in the same, similar or an easily substitutable strength" and can be used by the same route, "unless a prescriber determines and documents" a change that "produces a significant difference" for an identified patient (FDA GLP-1 page, April 1, 2026). Its 2018 guidance adds that it does not intend to act against a pharmacy that fills four or fewer prescriptions of a copy in a calendar month (FDA guidance).
Adding a second ingredient does not get around the rule. The FDA's example: semaglutide combined with vitamin B12 may be essentially a copy when both are given by the same route and "the amounts of semaglutide and vitamin B12 in the compounded drug product are within 10% of the strengths of the respective commercially available drug products." The documented significant difference has to be about the patient, not about the business model.
Why 503B office stock is closed
Outsourcing facilities supply clinics with drugs that are not tied to a named patient. With both drugs off the shortage list, a 503B facility could compound them from bulk only if they were on the 503B bulks list. They are not, and on May 1, 2026 the FDA proposed not to add them, saying that shortages are not "clinical need" in the statute's sense (91 FR 23431). The comment period closed July 30, 2026; as of November 3, 2026 the Federal Register shows no final notice. More in FDA's proposal on the 503B list and 503A vs 503B.
Marketing: what the FDA has warned telehealth companies about
The FDA's guidance page for telehealth companies (current as of June 15, 2026) lists claims it treats as false or misleading: "describing a compounded drug as a generic version of an FDA-approved drug or the same as a drug approved by FDA", calling a compounded drug FDA-approved, describing it as "clinically proven to produce the same result as the FDA-approved drug", claiming it is "sourced from an FDA-approved or FDA-licensed pharmacy or outsourcing facility", and "using branding on their website that falsely or misleadingly implies the telehealth company is the compounder" (FDA).
Those are the grounds of the 30 warning letters announced on March 3, 2026, which cited "claims implying sameness with FDA-approved products" and "obscuring product sourcing by advertising drug products branded with the telehealth firm's name" (FDA press release). A clinic's website, ads and intake scripts should be read against that list.
Ingredients, salts and research-use sellers
The FDA says salt forms, "including semaglutide sodium and semaglutide acetate, are different active ingredients than are used in the approved drugs", and that "Retatrutide and cagrilintide cannot be used in compounding under federal law" (FDA, current as of October 1, 2026). A 503A ingredient must also come from an FDA-registered manufacturer with a valid certificate of analysis.
Semaglutide and tirzepatide sold online "for research purposes only" are a criminal matter. In July 2026 a defendant in the Western District of Michigan was sentenced to 21 months over semaglutide and tirzepatide sold that way (DOJ, W.D. Mich.); see Research-use-only peptides.
North Carolina
North Carolina's Board of Pharmacy lets a pharmacy dispense a compounded drug only on a valid prescription, forbids offering compounded drugs to other entities for resale, and allows compounding for a practitioner's office use only as federal law permits (21 NCAC 46 .2801). An out-of-state pharmacy needs a Board permit before it ships even one dispensed prescription drug into the state (21 NCAC 46 .1607). A North Carolina clinic running a GLP-1 program should know which pharmacy compounds its product, under which section, and what its marketing says; see peptide and GLP-1 law for clinics.
Common questions
Is compounded tirzepatide banned?
Not entirely. Since the FDA's grace periods ended in March 2025, a 503A pharmacy may compound it only for an identified patient and not as a regular copy of Mounjaro or Zepbound unless the prescriber documents a significant difference for that patient. Outsourcing facilities have no route to compound it from bulk.
Is compounded semaglutide still legal?
Only within the 503A limits. The shortage ended February 21, 2025, the 503A grace period ended April 24, 2025 and the 503B grace period May 22, 2025. A pharmacy may compound it for an identified patient where the prescriber documents a significant difference from Ozempic or Wegovy.
Is compounded tirzepatide or semaglutide FDA-approved?
No. Compounded drugs are not FDA-approved, and the FDA has warned telehealth companies not to call them generic versions of, or the same as, the approved drugs.
Does adding vitamin B12 make compounded semaglutide legal?
Not by itself. The FDA said on April 1, 2026 that semaglutide with B12 may be essentially a copy when both are given by the same route and each is within 10% of the strength of the commercially available products.
Can a med spa buy compounded semaglutide as office stock?
Not lawfully from a 503B outsourcing facility compounding from bulk: neither semaglutide nor tirzepatide is on the 503B bulks list or the shortage list, and the FDA proposed in May 2026 to keep them off the list. 503A compounding is for identified patients.
Did the courts rule on the shortage decisions?
Yes. The Northern District of Texas ruled for the FDA in both cases, and on August 27, 2026 the Fifth Circuit affirmed both in unpublished opinions.
Update log
- November 3, 2026. Published. The FDA's GLP-1 compounding page (April 1, 2026), GLP-1 concerns page (October 1, 2026), telehealth promotion page (June 15, 2026), March 3, 2026 release and drug shortage database read at the source November 3, 2026; Federal Register docket FDA-2018-N-3240 checked (no final notice). Fifth Circuit opinions and the copies guidance as read October 30, 2026.
Sources
- FDA, FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (current as of April 1, 2026)
- FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (current as of October 1, 2026)
- 21 U.S.C. 353a (section 503A)
- 21 U.S.C. 353b (section 503B)
- FDA, Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A (guidance, January 2018)
- FDA, proposal not to include semaglutide, tirzepatide and liraglutide on the 503B Bulks List, 91 FR 23431 (May 1, 2026)
- FDA, extension of the comment period to July 30, 2026, 91 FR 38719 (June 26, 2026)
- Outsourcing Facilities Association v. FDA, No. 25-10600 (5th Cir. Aug. 27, 2026) (tirzepatide)
- Outsourcing Facilities Association v. FDA, No. 25-10758 (5th Cir. Aug. 27, 2026) (semaglutide)
- FDA, FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs (current as of June 15, 2026)
- FDA, warning letters to 30 telehealth companies (press release, March 3, 2026)
- FDA warning letter, Hims & Hers Health, Inc. (September 9, 2025)
- U.S. Attorney's Office, W.D. Mich., sentencing over "research purposes only" semaglutide and tirzepatide (July 23, 2026)
- FDA Drug Shortages database
- 21 NCAC 46 .2801 (North Carolina compounding rule; Cornell LII copy)
- 21 NCAC 46 .1607 (out-of-state pharmacies; Cornell LII copy)
Related
Running a GLP-1 program through a compounding pharmacy?
DPS Law advises clinics, telehealth companies and pharmacies on North Carolina and federal compounding and marketing rules. For another state's pharmacy or medical board rules, talk to a lawyer licensed in that state.